Clinical trial · Observational
Blinatumomab Consolidation in Real World
Real World Outcomes of Blinatumomab Consolidation in Patients With B-cell Acute Lymphoblastic Leukemia
NCT07117136CI-TRIAL-00120038recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This will be a multi-center registry for patients with B-ALL. Patient data will be collected both retrospectively and prospectively. The data forms and surveys will be built and managed through REDCap, a secure web application managed by the Clinical \& Translational Science Institute.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| B-Cell Acute Lymphoblastic Leukaemia | B Acute Lymphoblastic Leukemia | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- Patients who received Blinatumomab Therapy
- label
- Patients who did not receive Blinatumomab Therapy
Primary outcomes (1)
- measure
- Percentage of participants with complete remission
- timeFrame
- 5 years or e.g., 1 year after closure of study
- description
- Complete remission as defined by patients having no lymphoblasts in the marrow or blood
Secondary outcomes (1)
- measure
- Overall Survival
- timeFrame
- 5 years
- description
- Percentage of participants overall survival (OS). OS will be calculated from the time of diagnosis of to death from any cause, and patients will be censored if they were alive at the last follow-up
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * 1\) aged 18 years or older 2) diagnosed with B-ALL on or after December 1st 2022 3) Not received blinatumomab in an interventional clinical trial setting 4) Willing and able to give informed consent (or retrospective data for deceased patients Exclusion Criteria: * N/A
References
Publications (0)
Data not yet available
No reference posted for this study.